In the second quarter, Amgenâ€™s growth products like Prolia, Evenity, Repatha, Aimovig, Parsabiv and Otezla are expected to have driven sales.Also, increasing branded and generic competition for its legacy productslike Enbrel, Aranesp, Epogen, Neupogen, Neulasta and Sensipar are likely to have hurt the top line.